MTX 531
Alternative Names: MTX-531Latest Information Update: 16 Jul 2024
At a glance
- Originator Mekanistic Therapeutics
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Jul 2024 Pharmacodynamics data from a preclinical trial in Cancer released by MEKanistic Therapeutics
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Mekanistic Therapeutics plans a clinical trial for Cancer in late 2024